Can a 6-monthly administered biologic prevent age-related blindness?
As increasing numbers of people survive in relatively good health to older ages, the importance of diseases impacting their quality of life rise in significance. One such disease is age-related macular degeneration, (AMD), which in the ‘wet form’ of AMD or choroidal neovascularisation (CNV) is a major cause of vision impairment in the aging population. The basic ‘wet AMD’ aetiology is that leaky, new blood vessels from the choroid, penetrate into the retina and leak blood and fluid: obscuring the macula, which is the major centre of fine vision (acuity). So for many elderly sufferers of wet AMD their quality of life is drastically impacted. They may lose the ability to read or drive. Effective therapies are available to wet AMD sufferers with the advent of intravitreal (IVT) injections (directly into the eye) of biological inhibitors (anti-VEGFs) of the major cytokine driving the CNV and leaky vessel formation: Vascular Endothelial Growth Factor. However, the economic burden for health services able to provide such therapies and to the elderly patients is not simply the cost of the medicine, but the repeated frequent injections, ideally once a month or every two months for efficacy.
This requires multiple patient visits to Ophthalmology clinics, ensuing travel and time costs for Ophthalmologists, patients and carers. In clinical trials, the correct frequency of injection is adhered to: patient’s vision markedly improves often gaining visual acuity increases equivalent to 2-3 lines of improved vision on a standard eye chart. However, in the ‘real life’ situation, wet AMD patients are offered marketed anti-VEGF therapies which do not adhere to a regime of 6-12 IVT injections per year. The average number of injections per year is 2-3 or even less, and long term stabilisation of the improved vision seen in the ground breaking anti-VEGF trials is sadly not achieved in the real life setting with many elderly patients.
Efforts to address the longevity of action of anti-VEGF biologics have been actively pursued and include changing the molecule: to improve both its potency and half-life to reduce the frequency of injection. Using these approaches, an effective 3 monthly regime will reach the market soon. The eye is seen as a favourable organ to apply controlled release technologies to resolve this problem. We addressed many of the challenges of generating a 6-monthly administered sustained release formulation for an anti-VEGF biologic in our recent paper in Journal of Controlled Release. This work demonstrated that it was possible to load microparticles with sufficient amounts of a potent anti-VEGF molecule and inject IVT to show sustained release in a Cynomolgus pre-clinical model of wet AMD over 6 months at sufficient levels to protect eyes. Hurdles were overcome to keep a large protein active over 6 months in vivo.
Despite the approach being modelled to deliver clinical success, the Cynomolgus studies highlighted additional hurdles to be resolved: particulate ocular intolerability and resulting inflammation; particle migration to the front of the eye and delayed degradation of the delivery system matrix. Further work needs to move away from particulate delivery systems towards solidifying injectable gels with tuned release and degradation profiles to 6 months in the eye to make this premise a reality in man.
Cell and Gene Therapy Discovery Research, GlaxoSmithKline Medicines Research Centre,
Stevenage, United Kingdom
Single ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV model.
Adamson P, Wilde T, Dobrzynski E, Sychterz C, Polsky R, Kurali E, Haworth R, Tang CM, Korczynska J, Cook F, Papanicolaou I, Tsikna L, Roberts C, Hughes-Thomas Z, Walford J, Gibson D, Warrack J, Smal J, Verrijk R, Miller PE, Nork TM, Prusakiewicz J, Streit T, Sorden S, Struble C, Christian B, Catchpole IR
J Control Release. 2016 Dec 28
|Human blood brain barriers malfunction in… While the ancient Greeks and Romans already associated old age with dementia, it was not until 1901 that the German psychiatrist Alois Alzheimer diagnosed the first case of Alzheimer’s disease…|
|For Canadians access to eye care depends on where you live The Canada Health Act adopted in 1984 is based on the principle of universal healthcare coverage. In other words the Act promises physician and hospital services to all Canadian residents…|
|SOCS3 in neurons halts abnormal blood vessel… The leading cause of severe vision loss and blindness in the elderly, as well as in working age adults and in children is abnormal blood vessel growth in the retina.…|
|Rat model of small opaque eyes open the door to eye research Ocular diseases in elderly persons, such as cataract and age-related macular degeneration (AMD), one of the main causes of vision loss in developed nations, are paid great attention nowadays. The…|
|A small structure hidden in the brain that might… The choroid plexus is a hidden and often neglected, but important, structure in the brain. The choroid plexus hangs inside the brain ventricles which are filled with cerebrospinal fluid (CSF)…|
|Understanding why behaviours are challenging for… Dementia is a global health challenge that confronts health and social care systems today. It is characterised by global cognitive impairment. However, it is the disruption to daily living and…|